Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST

Allergy. 2021 Aug;76(8):2621-2624. doi: 10.1111/all.14872. Epub 2021 May 10.

Authors

Affiliations

¹ FundaciónCIDEA, Buenos Aires, Argentina.
² University of British Columbia, Vancouver, BC, Canada.
³ Respiratory Medicine Unit and Oxford Respiratory, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK.
⁴ Sanofi, Cambridge, MA, USA.
⁵ Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
⁶ Sanofi, Bridgewater, NJ, USA.

No abstract available

Keywords: asthma; asthma treatment; biologics; biomarkers; interleukins.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Humans

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
dupilumab

Associated data

ClinicalTrials.gov/NCT02414854